Want to see TSE:OPTI full AI Analyst Report?
OPTI Stock Chart & Stats
C$0.32
>-C$0.01(-2.38%)
At close: 4:00 PM EST
C$0.32
>-C$0.01(-2.38%)
Day’s Range― - ―
52-Week RangeC$4.35 - C$12.60
Previous CloseN/A
Volume13.36K
Average Volume (3M)169.72K
Market Cap
C$39.38M
Enterprise ValueC$26.11M
Total Cash (Recent Filing)C$106.71K
Total Debt (Recent Filing)C$6.57M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 28, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.68
Shares Outstanding5,625,899
10 Day Avg. Volume137,724
30 Day Avg. Volume169,715
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)5.70
Price to Sales (P/S)87.81
P/FCF Ratio-13.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained TTM revenue growth of ~19.8% indicates expanding commercial traction in regulated supply and services. If maintained, this revenue scale can help leverage fixed GMP-capacity, improve absorption of operating costs, and shorten the path to durable positive margins.
GMP-capable CDMO ServicesOperating GMP-capable facilities and offering CDMO services creates high entry barriers and recurring contract opportunities with clinical sponsors. This capability supports long-term revenue visibility and differentiation in a regulated psychedelics supply niche where quality/compliance are critical.
Regulated Market PositionA focus on supplying regulated psychedelics and supporting trial sponsors aligns with a growing structural market (clinical research and therapeutic development). Authorized supply and analytics services create durable demand from institutions that require compliant vendors.
Bears Say
Negative ProfitabilityPersistent negative gross profit and sizable operating losses indicate the business has not yet achieved sustainable unit economics. Continued unprofitability will deplete equity, pressure margins, and require clear evidence of structural margin improvement to rely less on external financing.
Weak Cash GenerationConsistently negative operating and free cash flow means the company depends on financing to fund operations and growth. This constrains reinvestment in capacity or R&D, raises dilution or refinancing risk, and limits resilience until cash flow turns sustainably positive.
Rising LeverageMaterial increase in leverage to ~1.33x and falling equity reduce financial flexibility. Higher debt amplifies downside risk, increases fixed obligations, and can restrict the company’s ability to invest in GMP expansions or withstand regulatory/commercial setbacks without dilutive or costly financing.
Optimi Health News
OPTI FAQ
What was Optimi Health’s price range in the past 12 months?
Optimi Health lowest stock price was C$4.35 and its highest was C$12.60 in the past 12 months.
What is Optimi Health’s market cap?
Optimi Health’s market cap is C$39.38M.
When is Optimi Health’s upcoming earnings report date?
Optimi Health’s upcoming earnings report date is Aug 28, 2026 which is in 38 days.
How were Optimi Health’s earnings last quarter?
Optimi Health released its earnings results on Jun 01, 2026. The company reported -C$0.36 earnings per share for the quarter, the consensus estimate of -C$0.36 by C$0.
Is Optimi Health overvalued?
According to Wall Street analysts Optimi Health’s price is currently Overvalued.
Does Optimi Health pay dividends?
Optimi Health does not currently pay dividends.
What is Optimi Health’s EPS estimate?
Optimi Health’s EPS estimate is -0.4.
How many shares outstanding does Optimi Health have?
Optimi Health has 5,625,899 shares outstanding.
What happened to Optimi Health’s price movement after its last earnings report?
Optimi Health reported an EPS of -C$0.36 in its last earnings report, expectations of -C$0.36. Following the earnings report the stock price went up 2.532%.
Which hedge fund is a major shareholder of Optimi Health?
Currently, no hedge funds are holding shares in TSE:OPTI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Optimi Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.54%
Trailing 12-Months
Company Description
Optimi Health
Optimi Health Corp. focuses on developing an integrated brand of functional mushrooms specifically for the Canadian health and wellness food markets. The company manages the entire process from the cultivation and extraction to the processing and distribution of these mushroom strains. Among the fungi varieties it offers are Lions Mane, Reishi, Turkey Tail, Chaga, and Cordyceps. Incorporated in 2020, the company was initially known as 1251418 BC Ltd. before officially changing its name to Optimi Health Corp. in August of that year. Its operations are headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
MediPharm Labs
―
PharmaCielo
―
Rubicon Organics
―
Avicanna
―